Loading...

Laura Esserman, MD

TitleProfessor
InstitutionUniversity of California San Francisco
DepartmentSurgery
Address1600 Divisadero
San Francisco CA 94115
Phone415-885-7691
vCardDownload vCard

    Collapse Overview 
    Collapse Overview
    Dr. Laura Esserman, M.D., M.B.A is a surgeon and breast cancer oncology specialist practicing at the UCSF Carol Franc Buck Breast Care Center where she has also held the position of Director since 1996. She co-leads the Breast Oncology Program, the largest of the UCSF Helen Diller Comprehensive Cancer Center's multidisciplinary programs. The program is comprised of 69 faculty members who represent 16 academic specialties and is internationally recognized and well-established with major initiatives in epidemiology, genetics, biology, therapeutics, and clinical cancer care. She is a professor of Surgery & Radiology at UCSF and faculty at the UCSF Helen Diller Family Comprehensive Cancer Center where she founded the program in Translational Informatics. As part of this program, her research has focused on bioinformatics, medical and clinical informatics, systems integration, and clinical care delivery.

    She has worked at UCSF to develop interdisciplinary teams of clinicians and researchers to bring the best care to patients and find the best platform to integrate translational research and improve the delivery of breast cancer care. In 2005, she received the NCI SPORE Investigator of the Year Award, an internationally recognized honor and designation.

    She is the Principle Investigator of the I-SPY TRIAL program, a multi-site neoadjuvant clinical trial that has evolved into a model for translational research and innovation in clinical trial design.

    Dr. Esserman has recently launched a University of California-wide breast cancer initiative called the Athena Breast Health Network, a project designed to follow 400,000 women from screening through treatment and outcomes, incorporating the latest in molecular testing and web-based tools into the course of care.

    Dr. Esserman is nationally and internationally known as a leader in the field of breast cancer and has published over 150 articles in peer-reviewed journals covering all aspects of breast health including information systems, immunology, decision making, health policy and the use of imaging. She speaks extensively at public and private forums within the U.S. and internationally. Overall, Dr. Esserman's research and writing tends to focus on the goal of giving patients better access to accurate information so that they can become partners in their health care.

    She is a member of President Obama’s Council of Advisors on Science and Technology (PCAST) Working Group on Advancing Innovation in Drug Development and Evaluation, which is studying how the federal government can best support science-based innovation in the process of drug development and regulatory evaluation. In addition, she is a contributing member of a “taskforce” for President Obama’s Council of Advisors on Science and Technology.

    Dr. Esserman received her Bachelor's degree in History of Science from Harvard University and completed her M.D. at Stanford University. She completed her surgery residency and oncology fellowship at Stanford University Medical Center. After her training, she joined the faculty at Stanford and received a Hartford fellowship to attend Stanford Business School where she received her M.B.A. in 1993. She then joined the faculty at the University of California, San Francisco.


    Collapse Research 
    Collapse Research Activities and Funding
    I-SPY2 +: Evolving the I-SPY 2 TRIAL to include MRI-directed, adaptive sequential treatment to optimize breast cancer outcomes
    NIH/NCI P01CA210961Sep 8, 2017 - Aug 31, 2022
    Role: Principal Investigator
    Elucidating the molecular and contextual basis for IDLE ultralow risk lesions and the tumor immune microenvironment of high risk in situ and invasive breast cancers
    NIH/NCI U01CA196406Sep 16, 2015 - Aug 31, 2020
    Role: Principal Investigator
    Modeling the Impact of Targeted Therapy Based on Breast Cancer Subtypes
    NIH/NCI U01CA187945Sep 18, 2014 - Aug 31, 2019
    Role: Principal Investigator
    Integrated Biomarkers to Characterize Breast Cancer Risk
    NIH/NCI U01CA111234Sep 20, 2004 - Jun 30, 2011
    Role: Principal Investigator

    Collapse ORNG Applications 
    Collapse Clinical Trials
    Collapse Global Health
    Collapse Websites
    Collapse In The News
    Collapse Featured Videos

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
    List All   |   Timeline
    1. Scheel JR, Kim E, Partridge SC, Lehman CD, Rosen MA, Bernreuter WK, Pisano ED, Marques HS, Morris EA, Weatherall PT, Polin SM, Newstead GM, Esserman L, Schnall MD, Hylton NM. MRI, Clinical Examination, and Mammography for Preoperative Assessment of Residual Disease and Pathologic Complete Response After Neoadjuvant Chemotherapy for Breast Cancer: ACRIN 6657 Trial. AJR Am J Roentgenol. 2018 Apr 30; 1-10. PMID: 29708782.
      View in: PubMed
    2. Chiu C, Aleshi P, Esserman L, Inglis-Arkell C, Yap E, Whitlock EL, Harbell MW. Improved analgesia and reduced post-operative nausea and vomiting after implementation of an enhanced recovery after surgery (ERAS) pathway for total mastectomy. BMC Anesthesiol. 2018 Apr 16; 18(1):41. PMID: 29661153.
      View in: PubMed
    3. Bidard FC, Michiels S, Riethdorf S, Mueller V, Esserman L, Lucci A, Naume B, Horiguchi J, Gisbert-Criado R, Sleijfer S, Toi M, Garcia-Saenz JA, Hartkopf A, Generali D, Rothé F, Smerage J, Muinelo-Romay L, Stebbing J, Viens P, Magbanua MJM, Hall CS, Engebraaten O, Takata D, Vidal-Martínez J, Onstenk W, Fujisawa N, Diaz-Rubio E, Taran FA, Cappelletti MR, Ignatiadis M, Proudhon C, Wolf DM, Bauldry JB, Borgen E, Nagaoka R, Carañana V, Kraan J, Maestro M, Brucker SY, Weber K, Reyal F, Amara D, Karhade MG, Mathiesen RR, Tokiniwa H, Llombart-Cussac A, Meddis A, Blanche P, d'Hollander K, Park JW, Pierga JY, Pantel K. Circulating Tumor Cells in Breast Cancer Patients Treated by Neoadjuvant Chemotherapy: A Meta-analysis. J Natl Cancer Inst. 2018 04 12. PMID: 29659933.
      View in: PubMed
    4. Price ER, Khoury AL, Esserman L, Joe BN, Alvarado MD. Initial Clinical Experience With an Inducible Magnetic Seed System for Preoperative Breast Lesion Localization. AJR Am J Roentgenol. 2018 Apr; 210(4):913-917. PMID: 29446680.
      View in: PubMed
    5. Lindström LS, Yau C, Czene K, Thompson CK, Hoadley KA, Van't Veer LJ, Balassanian R, Bishop JW, Carpenter PM, Chen YY, Datnow B, Hasteh F, Krings G, Lin F, Zhang Y, Nordenskjöld B, Stål O, Benz CC, Fornander T, Borowsky AD, Esserman L. Intratumor Heterogeneity of the Estrogen Receptor and the Long-term Risk of Fatal Breast Cancer. J Natl Cancer Inst. 2018 Jan 19. PMID: 29361175.
      View in: PubMed
    6. Peled AW, Sears M, Wang F, Foster RD, Alvarado M, Wong J, Ewing CA, Sbitany H, Esserman L, Fowble B. Complications After Total Skin-Sparing Mastectomy and Expander-Implant Reconstruction: Effects of Radiation Therapy on the Stages of Reconstruction. Ann Plast Surg. 2018 Jan; 80(1):10-13. PMID: 28671888.
      View in: PubMed
    7. Olshen A, Wolf D, Jones EF, Newitt D, van ‘t Veer LJ, Yau C, Esserman L, Wulfkuhle JD, Gallagher RI, Singer L, Petricoin EF, Hylton N, Park CC. Features of MRI stromal enhancement with neoadjuvant chemotherapy: a subgroup analysis of the ACRIN 6657/I-SPY TRIAL. J Med Imaging (Bellingham). 2018 01; 5(1):011014. PMID: 29296631.
      View in: PubMed
    8. Kwong A, Ho JCW, Shin VY, Kurian AW, Tai E, Esserman L, Weitzel JN, Lin PH, Field M, Domchek SM, Lo J, Ngan HYS, Ma ESK, Chan TL, Ford JM. Rapid detection of BRCA1/2 recurrent mutations in Chinese breast and ovarian cancer patients with multiplex SNaPshot genotyping panels. Oncotarget. 2018 Jan 30; 9(8):7832-7843. PMID: 29487695.
      View in: PubMed
    9. DeMichele A, Yee D, Esserman L. Mechanisms of Resistance to Neoadjuvant Chemotherapy in Breast Cancer. N Engl J Med. 2017 12 07; 377(23):2287-2289. PMID: 29211674.
      View in: PubMed
    10. Esserman L, Yau C, Thompson CK, van 't Veer LJ, Borowsky AD, Hoadley KA, Tobin NP, Nordenskjöld B, Fornander T, Stål O, Benz CC, Lindström LS. Use of Molecular Tools to Identify Patients With Indolent Breast Cancers With Ultralow Risk Over 2 Decades. JAMA Oncol. 2017 Nov 01; 3(11):1503-1510. PMID: 28662222.
      View in: PubMed
    11. Rice BA, Ver Hoeve ES, DeLuca AN, Esserman L, Rugo HS, Melisko ME. Registry study to assess hair loss prevention with the Penguin Cold Cap in breast cancer patients receiving chemotherapy. Breast Cancer Res Treat. 2018 Jan; 167(1):117-122. PMID: 28921303.
      View in: PubMed
    12. Esserman L. The WISDOM Study: breaking the deadlock in the breast cancer screening debate. NPJ Breast Cancer. 2017; 3:34. PMID: 28944288.
      View in: PubMed
    13. Bartelink IH, Prideaux B, Krings G, Wilmes L, Lee PRE, Bo P, Hann B, Coppé JP, Heditsian D, Swigart-Brown L, Jones EF, Magnitsky S, Keizer RJ, de Vries N, Rosing H, Pawlowska N, Thomas S, Dhawan M, Aggarwal R, Munster PN, Esserman L, Ruan W, Wu AHB, Yee D, Dartois V, Savic RM, Wolf DM, van 't Veer L. Heterogeneous drug penetrance of veliparib and carboplatin measured in triple negative breast tumors. Breast Cancer Res. 2017 Sep 11; 19(1):107. PMID: 28893315.
      View in: PubMed
    14. Wolf DM, Yau C, Sanil A, Glas A, Petricoin E, Wulfkuhle J, Severson TM, Linn S, Brown-Swigart L, Hirst G, Buxton M, DeMichele A, Hylton N, Symmans F, Yee D, Paoloni M, Esserman L, Berry D, Rugo H, Olopade O, van 't Veer L. DNA repair deficiency biomarkers and the 70-gene ultra-high risk signature as predictors of veliparib/carboplatin response in the I-SPY 2 breast cancer trial. NPJ Breast Cancer. 2017; 3:31. PMID: 28948212.
      View in: PubMed
    15. van 't Veer LJ, Yau C, Yu NY, Benz CC, Nordenskjöld B, Fornander T, Stål O, Esserman L, Lindström LS. Tamoxifen therapy benefit for patients with 70-gene signature high and low risk. Breast Cancer Res Treat. 2017 Nov; 166(2):593-601. PMID: 28776283.
      View in: PubMed
    16. Chien AJ, Chambers J, Mcauley F, Kaplan T, Letourneau J, Hwang J, Kim MO, Melisko ME, Rugo HS, Esserman L, Rosen MP. Erratum to: Fertility preservation with ovarian stimulation and time to treatment in women with stage II-III breast cancer receiving neoadjuvant therapy. Breast Cancer Res Treat. 2017 08; 165(1):161. PMID: 28660429.
      View in: PubMed
    17. Fowble B, Jairam AK, Wang F, Peled A, Alvarado M, Ewing C, Esserman L, Park C, Lazar A. Indications for Postmastectomy Radiation After Neoadjuvant Chemotherapy in ypN0 and ypN1-3 Axillary Node-Positive Women. Clin Breast Cancer. 2018 Feb; 18(1):e107-e113. PMID: 28830795.
      View in: PubMed
    18. Campbell JI, Yau C, Krass P, Moore D, Carey LA, Au A, Chhieng D, Giri D, Livasy C, Mies C, Rabban J, Sarode VR, Singh B, Esserman L, Chen YY. Comparison of residual cancer burden, American Joint Committee on Cancer staging and pathologic complete response in breast cancer after neoadjuvant chemotherapy: results from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657). Breast Cancer Res Treat. 2017 Aug; 165(1):181-191. PMID: 28577078.
      View in: PubMed
    19. Vidula N, Yau C, Li J, Esserman L, Rugo HS. Receptor activator of nuclear factor kappa B (RANK) expression in primary breast cancer correlates with recurrence-free survival and development of bone metastases in I-SPY1 (CALGB 150007/150012; ACRIN 6657). Breast Cancer Res Treat. 2017 Aug; 165(1):129-138. PMID: 28577080.
      View in: PubMed
    20. Chien AJ, Chambers J, Mcauley F, Kaplan T, Letourneau J, Hwang J, Kim MO, Melisko ME, Rugo HS, Esserman L, Rosen MP. Fertility preservation with ovarian stimulation and time to treatment in women with stage II-III breast cancer receiving neoadjuvant therapy. Breast Cancer Res Treat. 2017 Aug; 165(1):151-159. PMID: 28503722.
      View in: PubMed
    21. Melisko ME, Goldman ME, Hwang J, De Luca A, Fang S, Esserman L, Chien AJ, Park JW, Rugo HS. Vaginal Testosterone Cream vs Estradiol Vaginal Ring for Vaginal Dryness or Decreased Libido in Women Receiving Aromatase Inhibitors for Early-Stage Breast Cancer: A Randomized Clinical Trial. JAMA Oncol. 2017 Mar 01; 3(3):313-319. PMID: 27832260.
      View in: PubMed
    22. Rugo HS, Klein P, Melin SA, Hurvitz SA, Melisko ME, Moore A, Park G, Mitchel J, Bågeman E, D'Agostino RB, Ver Hoeve ES, Esserman L, Cigler T. Association Between Use of a Scalp Cooling Device and Alopecia After Chemotherapy for Breast Cancer. JAMA. 2017 02 14; 317(6):606-614. PMID: 28196257.
      View in: PubMed
    23. Shieh Y, Eklund M, Madlensky L, Sawyer SD, Thompson CK, Stover Fiscalini A, Ziv E, Van't Veer LJ, Esserman L, Tice JA. Breast Cancer Screening in the Precision Medicine Era: Risk-Based Screening in a Population-Based Trial. J Natl Cancer Inst. 2017 01; 109(5). PMID: 28130475.
      View in: PubMed
    24. Ellis MJ, Suman VJ, Hoog J, Goncalves R, Sanati S, Creighton CJ, DeSchryver K, Crouch E, Brink A, Watson M, Luo J, Tao Y, Barnes M, Dowsett M, Budd GT, Winer E, Silverman P, Esserman L, Carey L, Ma CX, Unzeitig G, Pluard T, Whitworth P, Babiera G, Guenther JM, Dayao Z, Ota D, Leitch M, Olson JA, Allred DC, Hunt K. Ki67 Proliferation Index as a Tool for Chemotherapy Decisions During and After Neoadjuvant Aromatase Inhibitor Treatment of Breast Cancer: Results From the American College of Surgeons Oncology Group Z1031 Trial (Alliance). J Clin Oncol. 2017 Apr 01; 35(10):1061-1069. PMID: 28045625.
      View in: PubMed
    25. Jones EF, Ray KM, Li W, Seo Y, Franc BL, Chien AJ, Esserman L, Pampaloni MH, Joe BN, Hylton NM. Dedicated Breast Positron Emission Tomography for the Evaluation of Early Response to Neoadjuvant Chemotherapy in Breast Cancer. Clin Breast Cancer. 2017 06; 17(3):e155-e159. PMID: 28110902.
      View in: PubMed
    26. Bolan PJ, Kim E, Herman BA, Newstead GM, Rosen MA, Schnall MD, Pisano ED, Weatherall PT, Morris EA, Lehman CD, Garwood M, Nelson MT, Yee D, Polin SM, Esserman L, Gatsonis CA, Metzger GJ, Newitt DC, Partridge SC, Hylton NM. MR spectroscopy of breast cancer for assessing early treatment response: Results from the ACRIN 6657 MRS trial. J Magn Reson Imaging. 2017 Jul; 46(1):290-302. PMID: 27981651.
      View in: PubMed
    27. Wang F, Chin R, Piper M, Esserman L, Sbitany H. Do Prolonged Prophylactic Antibiotics Reduce the Incidence of Surgical-Site Infections in Immediate Prosthetic Breast Reconstruction? Plast Reconstr Surg. 2016 Dec; 138(6):1141-1149. PMID: 27537226.
      View in: PubMed
    28. Li W, Arasu V, Newitt DC, Jones EF, Wilmes L, Gibbs J, Kornak J, Joe BN, Esserman L, Hylton NM. Effect of MR Imaging Contrast Thresholds on Prediction of Neoadjuvant Chemotherapy Response in Breast Cancer Subtypes: A Subgroup Analysis of the ACRIN 6657/I-SPY 1 TRIAL. Tomography. 2016 Dec; 2(4):378-387. PMID: 28066808.
      View in: PubMed
    29. Amara D, Wolf DM, van 't Veer L, Esserman L, Campbell M, Yau C. Co-expression modules identified from published immune signatures reveal five distinct immune subtypes in breast cancer. Breast Cancer Res Treat. 2017 01; 161(1):41-50. PMID: 27815749.
      View in: PubMed
    30. Campbell MJ, Baehner F, O'Meara T, Ojukwu E, Han B, Mukhtar R, Tandon V, Endicott M, Zhu Z, Wong J, Krings G, Au A, Gray JW, Esserman L. Characterizing the immune microenvironment in high-risk ductal carcinoma in situ of the breast. Breast Cancer Res Treat. 2017 01; 161(1):17-28. PMID: 27785654.
      View in: PubMed
    31. Berry D, Esserman L. Adaptive Randomization of Neratinib in Early Breast Cancer. N Engl J Med. 2016 10 20; 375(16):1592-3. PMID: 27797314.
      View in: PubMed
    32. Esserman L. The I-SPY approach to drug development. Clin Adv Hematol Oncol. 2016 Oct; 14(10):782-784. PMID: 27930629.
      View in: PubMed
    33. Esserman L, Thompson IM. Laura Esserman and Ian Thompson Discuss Strategies for Screening and Treatment of Early-Stage Cancers, and How Clinicians Can Learn From Each Other's Experiences. Oncology (Williston Park). 2016 09 15; 30(9):770, 785-6. PMID: 27633408.
      View in: PubMed
    34. Rugo HS, Olopade OI, DeMichele A, Yau C, van 't Veer LJ, Buxton MB, Hogarth M, Hylton NM, Paoloni M, Perlmutter J, Symmans WF, Yee D, Chien AJ, Wallace AM, Kaplan HG, Boughey JC, Haddad TC, Albain KS, Liu MC, Isaacs C, Khan QJ, Lang JE, Viscusi RK, Pusztai L, Moulder SL, Chui SY, Kemmer KA, Elias AD, Edmiston KK, Euhus DM, Haley BB, Nanda R, Northfelt DW, Tripathy D, Wood WC, Ewing C, Schwab R, Lyandres J, Davis SE, Hirst GL, Sanil A, Berry DA, Esserman L. Adaptive Randomization of Veliparib-Carboplatin Treatment in Breast Cancer. N Engl J Med. 2016 Jul 07; 375(1):23-34. PMID: 27406347.
      View in: PubMed
    35. Park JW, Liu MC, Yee D, Yau C, van 't Veer LJ, Symmans WF, Paoloni M, Perlmutter J, Hylton NM, Hogarth M, DeMichele A, Buxton MB, Chien AJ, Wallace AM, Boughey JC, Haddad TC, Chui SY, Kemmer KA, Kaplan HG, Isaacs C, Nanda R, Tripathy D, Albain KS, Edmiston KK, Elias AD, Northfelt DW, Pusztai L, Moulder SL, Lang JE, Viscusi RK, Euhus DM, Haley BB, Khan QJ, Wood WC, Melisko M, Schwab R, Helsten T, Lyandres J, Davis SE, Hirst GL, Sanil A, Esserman L, Berry DA. Adaptive Randomization of Neratinib in Early Breast Cancer. N Engl J Med. 2016 Jul 07; 375(1):11-22. PMID: 27406346.
      View in: PubMed
    36. Esserman L. When Less Is Better, but Physicians Are Afraid Not to Intervene. JAMA Intern Med. 2016 07 01; 176(7):888-9. PMID: 27243587.
      View in: PubMed
    37. Katchman BA, Barderas R, Alam R, Chowell D, Field MS, Esserman L, Wallstrom G, LaBaer J, Cramer DW, Hollingsworth MA, Anderson KS. Proteomic mapping of p53 immunogenicity in pancreatic, ovarian, and breast cancers. Proteomics Clin Appl. 2016 07; 10(7):720-31. PMID: 27121307.
      View in: PubMed
    38. Piper ML, Esserman L, Sbitany H, Peled AW. Outcomes Following Oncoplastic Reduction Mammoplasty: A Systematic Review. Ann Plast Surg. 2016 May; 76 Suppl 3:S222-6. PMID: 26808743.
      View in: PubMed
    39. Shieh Y, Eklund M, Sawaya GF, Black WC, Kramer BS, Esserman L. Population-based screening for cancer: hope and hype. Nat Rev Clin Oncol. 2016 09; 13(9):550-65. PMID: 27071351.
      View in: PubMed
    40. Borowsky A, Esserman L. When the Gold Standard Loses Its Luster, Perhaps It Is Time to Change Nomenclature. Ann Intern Med. 2016 05 17; 164(10):694-5. PMID: 26999728.
      View in: PubMed
    41. Esserman L, Yau C. Treatment and Long-Term Risks for Patients With a Diagnosis of Ductal Carcinoma In Situ-Reply. JAMA Oncol. 2016 Mar; 2(3):395-6. PMID: 26967177.
      View in: PubMed
    42. Lo WC, Li W, Jones EF, Newitt DC, Kornak J, Wilmes LJ, Esserman L, Hylton NM. Effect of Imaging Parameter Thresholds on MRI Prediction of Neoadjuvant Chemotherapy Response in Breast Cancer Subtypes. PLoS One. 2016; 11(2):e0142047. PMID: 26886725; PMCID: PMC4757528.
    43. Chien AJ, Cockerill A, Fancourt C, Schmidt E, Moasser MM, Rugo HS, Melisko ME, Ko AH, Kelley RK, Korn WM, Esserman L, van't Veer L, Yau C, Wolf DM, Munster PN. A phase 1b study of the Akt-inhibitor MK-2206 in combination with weekly paclitaxel and trastuzumab in patients with advanced HER2-amplified solid tumor malignancies. Breast Cancer Res Treat. 2016 Feb; 155(3):521-30. PMID: 26875185.
      View in: PubMed
    44. Shieh Y, Eklund M, Esserman L. Detection of ductal carcinoma in situ and subsequent interval cancers. BMJ. 2016 Feb 01; 352:i551. PMID: 26834245.
      View in: PubMed
    45. Merrill AL, Esserman L, Morrow M. CLINICAL DECISIONS. Ductal Carcinoma In Situ. N Engl J Med. 2016 Jan 28; 374(4):390-2. PMID: 26816018.
      View in: PubMed
    46. Wang F, Peled AW, Chin R, Fowble B, Alvarado M, Ewing C, Esserman L, Foster R, Sbitany H. The Impact of Radiation Therapy, Lymph Node Dissection, and Hormonal Therapy on Outcomes of Tissue Expander-Implant Exchange in Prosthetic Breast Reconstruction. Plast Reconstr Surg. 2016 Jan; 137(1):1-9. PMID: 26368331.
      View in: PubMed
    47. Esserman L, Gallant E, Alvarado M. Less Is More: The Evolving Surgical Approach to Breast Cancer. Am Soc Clin Oncol Educ Book. 2016; 35:e5-e10. PMID: 27249759.
      View in: PubMed
    48. Sbitany H, Wang F, Peled AW, Alvarado M, Ewing CA, Esserman L, Foster RD. Tissue Expander Reconstruction After Total Skin-Sparing Mastectomy: Defining the Effects of Coverage Technique on Nipple/Areola Preservation. Ann Plast Surg. 2016 Jan; 77(1):17-24. PMID: 25057918.
      View in: PubMed
    49. DeMichele A, Yee D, Paoloni M, Berry D, Esserman L. Neoadjuvant as Future for Drug Development in Breast Cancer--Response. Clin Cancer Res. 2016 Jan 01; 22(1):269. PMID: 26728411.
      View in: PubMed
    50. Johnson J, Esserman L, Ewing C, Alvarado M, Park C, Fowble B. Sentinel Lymph Node Mapping in Post-Mastectomy Chest Wall Recurrences: Influence on Radiation Treatment Fields and Outcome. Ann Surg Oncol. 2016 Mar; 23(3):715-21. PMID: 26714943.
      View in: PubMed
    51. Hylton NM, Gatsonis CA, Rosen MA, Lehman CD, Newitt DC, Partridge SC, Bernreuter WK, Pisano ED, Morris EA, Weatherall PT, Polin SM, Newstead GM, Marques HS, Esserman L, Schnall MD. Neoadjuvant Chemotherapy for Breast Cancer: Functional Tumor Volume by MR Imaging Predicts Recurrence-free Survival-Results from the ACRIN 6657/CALGB 150007 I-SPY 1 TRIAL. Radiology. 2016 Apr; 279(1):44-55. PMID: 26624971; PMCID: PMC4819899 [Available on 04/01/17].
    52. Esserman L, Yau C. Rethinking the Standard for Ductal Carcinoma In Situ Treatment. JAMA Oncol. 2015 Oct; 1(7):881-3. PMID: 26291410.
      View in: PubMed
    53. Wang F, Amara D, Peled AW, Sbitany H, Foster RD, Ewing CA, Alvarado M, Esserman L. Negative Genetic Testing Does Not Deter Contralateral Prophylactic Mastectomy in Younger Patients with Greater Family Histories of Breast Cancer. Ann Surg Oncol. 2015 Oct; 22(10):3338-45. PMID: 26215194.
      View in: PubMed
    54. Chien AJ, Duralde E, Hwang R, Tsung K, Kao CN, Rugo HS, Melisko ME, Esserman L, Munster PN, Cedars M, Kerlikowske K, McCulloch CE, Rosen MP. Association of tamoxifen use and ovarian function in patients with invasive or pre-invasive breast cancer. Breast Cancer Res Treat. 2015 Aug; 153(1):173-81. PMID: 26208485.
      View in: PubMed
    55. Provenzano E, Bossuyt V, Viale G, Cameron D, Badve S, Denkert C, MacGrogan G, Penault-Llorca F, Boughey J, Curigliano G, Dixon JM, Esserman L, Fastner G, Kuehn T, Peintinger F, von Minckwitz G, White J, Yang W, Symmans WF. Standardization of pathologic evaluation and reporting of postneoadjuvant specimens in clinical trials of breast cancer: recommendations from an international working group. Mod Pathol. 2015 Sep; 28(9):1185-201. PMID: 26205180.
      View in: PubMed
    56. Price ER, Wong J, Mukhtar R, Hylton N, Esserman L. How to use magnetic resonance imaging following neoadjuvant chemotherapy in locally advanced breast cancer. World J Clin Cases. 2015 Jul 16; 3(7):607-13. PMID: 26244152; PMCID: PMC4517335.
    57. Peled AW, Wang F, Foster RD, Alvarado M, Ewing CA, Sbitany H, Esserman L. Expanding the Indications for Total Skin-Sparing Mastectomy: Is It Safe for Patients with Locally Advanced Disease? Ann Surg Oncol. 2016 Jan; 23(1):87-91. PMID: 26170194.
      View in: PubMed
    58. Vaidya JS, Bulsara M, Wenz F, Joseph D, Saunders C, Massarut S, Flyger H, Eiermann W, Alvarado M, Esserman L, Falzon M, Brew-Graves C, Potyka I, Tobias JS, Baum M. In Regard to Hepel and Wazer. Int J Radiat Oncol Biol Phys. 2015 Aug 01; 92(5):953-954. PMID: 26194663.
      View in: PubMed
    59. Mukhtar RA, Wong JM, Esserman L. Preventing Overdiagnosis and Overtreatment: Just the Next Step in the Evolution of Breast Cancer Care. J Natl Compr Canc Netw. 2015 Jun; 13(6):737-43. PMID: 26085389.
      View in: PubMed
    60. Magbanua MJ, Wolf DM, Yau C, Davis SE, Crothers J, Au A, Haqq CM, Livasy C, Rugo HS. Serial expression analysis of breast tumors during neoadjuvant chemotherapy reveals changes in cell cycle and immune pathways associated with recurrence and response. Breast Cancer Res. 2015 May 29; 17:73. PMID: 26021444; PMCID: PMC4479083.
    61. Amara D, Peled AW, Wang F, Ewing CA, Alvarado M, Esserman L. Tumor Involvement of the Nipple in Total Skin-Sparing Mastectomy: Strategies for Management. Ann Surg Oncol. 2015 Nov; 22(12):3803-8. PMID: 26023040.
      View in: PubMed
    62. Belkora J, Volz S, Loth M, Teng A, Zarin-Pass M, Moore D, Esserman L. Coaching patients in the use of decision and communication aids: RE-AIM evaluation of a patient support program. BMC Health Serv Res. 2015 May 28; 15:209. PMID: 26017564; PMCID: PMC4446845.
    63. Piper M, Peled AW, Sbitany H, Foster RD, Esserman L, Price ER. Comparison of Mammographic Findings Following Oncoplastic Mammoplasty and Lumpectomy Without Reconstruction. Ann Surg Oncol. 2016 Jan; 23(1):65-71. PMID: 25994209.
      View in: PubMed
    64. Raghavan S, Peled AW, Hansen SL, Esserman L, Sbitany H. Approaches to microvascular breast reconstruction after total skin-sparing mastectomy: a comparison of techniques. Ann Plast Surg. 2015 May; 74 Suppl 1:S46-51. PMID: 25875911.
      View in: PubMed
    65. Fowble B, Park C, Wang F, Peled A, Alvarado M, Ewing C, Esserman L, Foster R, Sbitany H, Hanlon A. Rates of Reconstruction Failure in Patients Undergoing Immediate Reconstruction With Tissue Expanders and/or Implants and Postmastectomy Radiation Therapy. Int J Radiat Oncol Biol Phys. 2015 Jul 01; 92(3):634-41. PMID: 25936815.
      View in: PubMed
    66. Vaidya JS, Bulsara M, Wenz F, Joseph D, Saunders C, Massarut S, Flyger H, Eiermann W, Alvarado M, Esserman L, Falzon M, Brew-Graves C, Potyka I, Tobias JS, Baum M. Pride, Prejudice, or Science: Attitudes Towards the Results of the TARGIT-A Trial of Targeted Intraoperative Radiation Therapy for Breast Cancer. Int J Radiat Oncol Biol Phys. 2015 Jul 01; 92(3):491-7. PMID: 26068479; PMCID: PMC4464618.
    67. Wang F, Alvarado M, Ewing C, Esserman L, Foster R, Sbitany H. The impact of breast mass on outcomes of total skin-sparing mastectomy and immediate tissue expander-based breast reconstruction. Plast Reconstr Surg. 2015 Mar; 135(3):672-9. PMID: 25719689.
      View in: PubMed
    68. DeMichele A, Yee D, Berry DA, Albain KS, Benz CC, Boughey J, Buxton M, Chia SK, Chien AJ, Chui SY, Clark A, Edmiston K, Elias AD, Forero-Torres A, Haddad TC, Haley B, Haluska P, Hylton NM, Isaacs C, Kaplan H, Korde L, Leyland-Jones B, Liu MC, Melisko M, Minton SE, Moulder SL, Nanda R, Olopade OI, Paoloni M, Park JW, Parker BA, Perlmutter J, Petricoin EF, Rugo H, Symmans F, Tripathy D, van't Veer LJ, Viscusi RK, Wallace A, Wolf D, Yau C, Esserman L. The Neoadjuvant Model Is Still the Future for Drug Development in Breast Cancer. Clin Cancer Res. 2015 Jul 01; 21(13):2911-5. PMID: 25712686; PMCID: PMC4490043.
    69. Warner JL, Maddux SE, Hughes KS, Krauss JC, Yu PP, Shulman LN, Mayer DK, Hogarth M, Shafarman M, Stover Fiscalini A, Esserman L, Alschuler L, Koromia GA, Gonzaga Z, Ambinder EP. Development, implementation, and initial evaluation of a foundational open interoperability standard for oncology treatment planning and summarization. J Am Med Inform Assoc. 2015 May; 22(3):577-86. PMID: 25604811.
      View in: PubMed
    70. Langford DJ, Schmidt B, Levine JD, Abrams G, Elboim C, Esserman L, Hamolsky D, Mastick J, Paul SM, Cooper B, Kober K, Dodd M, Dunn L, Aouizerat B, Miaskowski C. Preoperative Breast Pain Predicts Persistent Breast Pain and Disability After Breast Cancer Surgery. J Pain Symptom Manage. 2015 Jun; 49(6):981-94. PMID: 25527442; PMCID: PMC4470873.
    71. Marks JR, Anderson KS, Engstrom P, Godwin AK, Esserman L, Longton G, Iversen ES, Mathew A, Patriotis C, Pepe MS. Construction and analysis of the NCI-EDRN breast cancer reference set for circulating markers of disease. Cancer Epidemiol Biomarkers Prev. 2015 Feb; 24(2):435-41. PMID: 25471344; PMCID: PMC4323938.
    72. Wheelock AE, Bock MA, Martin EL, Hwang J, Ernest ML, Rugo HS, Esserman L, Melisko ME. SIS.NET: a randomized controlled trial evaluating a web-based system for symptom management after treatment of breast cancer. Cancer. 2015 Mar 15; 121(6):893-9. PMID: 25469673.
      View in: PubMed
    73. Lang JE, Scott JH, Wolf DM, Novak P, Punj V, Magbanua MJ, Zhu W, Mineyev N, Haqq CM, Crothers JR, Esserman L, Tripathy D, van 't Veer L, Park JW. Expression profiling of circulating tumor cells in metastatic breast cancer. Breast Cancer Res Treat. 2015 Jan; 149(1):121-31. PMID: 25432738; PMCID: PMC4698170.
    74. Sbitany H, Wang F, Peled AW, Lentz R, Alvarado M, Ewing CA, Esserman L, Fowble B, Foster RD. Immediate implant-based breast reconstruction following total skin-sparing mastectomy: defining the risk of preoperative and postoperative radiation therapy for surgical outcomes. Plast Reconstr Surg. 2014 Sep; 134(3):396-404. PMID: 25158699.
      View in: PubMed
    75. Eklund M, O'Donoghue C, Esserman L. Aggregate cost of mammography screening in the United States. Ann Intern Med. 2014 Aug 19; 161(4):305. PMID: 25133367.
      View in: PubMed
    76. Degnim AC, Hoskin TL, Brahmbhatt RD, Warren-Peled A, Loprinzi M, Pavey ES, Boughey JC, Hieken TJ, Jacobson S, Lemaine V, Jakub JW, Irwin C, Foster RD, Sbitany H, Saint-Cyr M, Duralde E, Ramaker S, Chin R, Sieg M, Wildeman M, Scow JS, Patel R, Ballman K, Baddour LM, Esserman L. Randomized trial of drain antisepsis after mastectomy and immediate prosthetic breast reconstruction. Ann Surg Oncol. 2014 Oct; 21(10):3240-8. PMID: 25096386; PMCID: PMC4373621.
    77. Esserman L, Hayes M, Alvarado M. Haste makes waste, but lack of urgency is opportunity lost. Breast Cancer Res Treat. 2014 Aug; 147(1):223-4. PMID: 25062705.
      View in: PubMed
    78. Peled AW, Foster RD, Ligh C, Esserman L, Fowble B, Sbitany H. Impact of total skin-sparing mastectomy incision type on reconstructive complications following radiation therapy. Plast Reconstr Surg. 2014 Aug; 134(2):169-75. PMID: 24732652.
      View in: PubMed
    79. Esserman L, O'Kane ME. Moving beyond the breast cancer screening debate. J Womens Health (Larchmt). 2014 Aug; 23(8):629-30. PMID: 25068713.
      View in: PubMed
    80. Wang F, Peled AW, Garwood E, Fiscalini AS, Sbitany H, Foster RD, Alvarado M, Ewing C, Hwang ES, Esserman L. Total skin-sparing mastectomy and immediate breast reconstruction: an evolution of technique and assessment of outcomes. Ann Surg Oncol. 2014 Oct; 21(10):3223-30. PMID: 25052246.
      View in: PubMed
    81. Sbitany H, Wang F, Saeed L, Alvarado M, Ewing CA, Esserman L, Foster RD. Immediate implant-based breast reconstruction following total skin-sparing mastectomy in women with a history of augmentation mammaplasty: assessing the safety profile. Plast Reconstr Surg. 2014 Jul; 134(1):1-9. PMID: 24622575.
      View in: PubMed
    82. Elias SG, Adams A, Wisner DJ, Esserman L, van't Veer LJ, Mali WP, Gilhuijs KG, Hylton NM. Imaging features of HER2 overexpression in breast cancer: a systematic review and meta-analysis. Cancer Epidemiol Biomarkers Prev. 2014 Aug; 23(8):1464-83. PMID: 24807204.
      View in: PubMed
    83. Kerlikowske K, O'Kane ME, Esserman L. Fifty years of age-based screening: time for a new risk-based screening approach. Evid Based Med. 2014 Oct; 19(5):183. PMID: 24785471.
      View in: PubMed
    84. Peled AW, Sbitany H, Foster RD, Esserman L. Oncoplastic mammoplasty as a strategy for reducing reconstructive complications associated with postmastectomy radiation therapy. Breast J. 2014 May-Jun; 20(3):302-7. PMID: 24750512.
      View in: PubMed
    85. Peled AW, Duralde E, Foster RD, Fiscalini AS, Esserman L, Hwang ES, Sbitany H. Patient-reported outcomes and satisfaction after total skin-sparing mastectomy and immediate expander-implant reconstruction. Ann Plast Surg. 2014 May; 72 Suppl 1:S48-52. PMID: 24317238.
      View in: PubMed
    86. Cureton EL, Yau C, Alvarado MD, Krontiras H, Ollila DW, Ewing CA, Monnier S, Esserman L. Local recurrence rates are low in high-risk neoadjuvant breast cancer in the I-SPY 1 Trial (CALGB 150007/150012; ACRIN 6657). Ann Surg Oncol. 2014 Sep; 21(9):2889-96. PMID: 24788555; PMCID: PMC4303244.
    87. Esserman L, Thompson IM, Reid B, Nelson P, Ransohoff DF, Welch HG, Hwang S, Berry DA, Kinzler KW, Black WC, Bissell M, Parnes H, Srivastava S. Addressing overdiagnosis and overtreatment in cancer: a prescription for change. Lancet Oncol. 2014 May; 15(6):e234-42. PMID: 24807866; PMCID: PMC4322920.
    88. Esserman L, DeMichele A. Accelerated approval for pertuzumab in the neoadjuvant setting: winds of change? Clin Cancer Res. 2014 Jul 15; 20(14):3632-6. PMID: 24748554.
      View in: PubMed
    89. Clark AS, Chen J, Kapoor S, Friedman C, Mies C, Esserman L, DeMichele A. Pretreatment vitamin D level and response to neoadjuvant chemotherapy in women with breast cancer on the I-SPY trial (CALGB 150007/150015/ACRIN6657). Cancer Med. 2014 Jun; 3(3):693-701. PMID: 24719175; PMCID: PMC4101761.
    90. Esserman L, Alvarado M. Setting a research agenda for ductal carcinoma in situ that meets the current need for change. Ann Intern Med. 2014 Apr 01; 160(7):511-2. PMID: 24566896.
      View in: PubMed
    91. Wang F, Peled A, Foster R, Wang E, Ewing C, Alvarado M, Esserman L, Sbitany H. Abstract 124: outcomes of total skin-sparing mastectomy and reconstruction in 924 breasts over 11 years. Plast Reconstr Surg. 2014 Mar; 133(3 Suppl):139. PMID: 25942235.
      View in: PubMed
    92. Jackson SA, Davis AA, Li J, Yi N, McCormick SR, Grant C, Fallen T, Crawford B, Loranger K, Litton J, Arun B, Vande Wydeven K, Sidani A, Farmer K, Sanders M, Hoskins K, Nussbaum R, Esserman L, Garber JE, Kaklamani VG. Characteristics of individuals with breast cancer rearrangements in BRCA1 and BRCA2. Cancer. 2014 May 15; 120(10):1557-64. PMID: 24522996.
      View in: PubMed
    93. O'Donoghue C, Eklund M, Ozanne EM, Esserman L. Aggregate cost of mammography screening in the United States: comparison of current practice and advocated guidelines. Ann Intern Med. 2014 Feb 04; 160(3):145. PMID: 24658691; PMCID: PMC4142190.
    94. Newitt DC, Aliu SO, Witcomb N, Sela G, Kornak J, Esserman L, Hylton NM. Real-Time Measurement of Functional Tumor Volume by MRI to Assess Treatment Response in Breast Cancer Neoadjuvant Clinical Trials: Validation of the Aegis SER Software Platform. Transl Oncol. 2014 Feb; 7(1):94-100. PMID: 24772212; PMCID: PMC3998689.
    95. Ozanne EM, Howe R, Omer Z, Esserman L. Development of a personalized decision aid for breast cancer risk reduction and management. BMC Med Inform Decis Mak. 2014 Jan 14; 14:4. PMID: 24422989; PMCID: PMC3899602.
    96. Esserman L, Thompson IM, Reid BJ. Changing the terminology of cancer--reply. JAMA. 2014 Jan 08; 311(2):203. PMID: 24399568.
      View in: PubMed
    97. Jafri NF, Newitt DC, Kornak J, Esserman L, Joe BN, Hylton NM. Optimized breast MRI functional tumor volume as a biomarker of recurrence-free survival following neoadjuvant chemotherapy. J Magn Reson Imaging. 2014 Aug; 40(2):476-82. PMID: 24347097; PMCID: PMC4507716.
    98. Wells CJ, O'Donoghue C, Ojeda-Fournier H, Retallack HE, Esserman L. Evolving paradigm for imaging, diagnosis, and management of DCIS. J Am Coll Radiol. 2013 Dec; 10(12):918-23. PMID: 24295941.
      View in: PubMed
    99. Alvarado MD, Conolly J, Park C, Sakata T, Mohan AJ, Harrison BL, Hayes M, Esserman L, Ozanne EM. Patient preferences regarding intraoperative versus external beam radiotherapy following breast-conserving surgery. Breast Cancer Res Treat. 2014 Jan; 143(1):135-40. PMID: 24292868.
      View in: PubMed
    100. Vaidya JS, Wenz F, Bulsara M, Tobias JS, Joseph DJ, Keshtgar M, Flyger HL, Massarut S, Alvarado M, Saunders C, Eiermann W, Metaxas M, Sperk E, Sütterlin M, Brown D, Esserman L, Roncadin M, Thompson A, Dewar JA, Holtveg HM, Pigorsch S, Falzon M, Harris E, Matthews A, Brew-Graves C, Potyka I, Corica T, Williams NR, Baum M. Risk-adapted targeted intraoperative radiotherapy versus whole-breast radiotherapy for breast cancer: 5-year results for local control and overall survival from the TARGIT-A randomised trial. Lancet. 2014 Feb 15; 383(9917):603-13. PMID: 24224997.
      View in: PubMed
    101. Eklund M, Esserman L. Screening: biology dictates the fate of young women with breast cancer. Nat Rev Clin Oncol. 2013 Dec; 10(12):673-5. PMID: 24189468.
      View in: PubMed
    102. Campbell MJ, Wolf D, Mukhtar RA, Tandon V, Yau C, Au A, Baehner F, van't Veer L, Berry D, Esserman L. The prognostic implications of macrophages expressing proliferating cell nuclear antigen in breast cancer depend on immune context. PLoS One. 2013; 8(10):e79114. PMID: 24205370; PMCID: PMC3812150.
    103. Omer ZB, Hwang ES, Esserman L, Howe R, Ozanne EM. Impact of ductal carcinoma in situ terminology on patient treatment preferences. JAMA Intern Med. 2013 Oct 28; 173(19):1830-1. PMID: 23978843.
      View in: PubMed
    104. Peled AW, Irwin CS, Hwang ES, Ewing CA, Alvarado M, Esserman L. Total skin-sparing mastectomy in BRCA mutation carriers. Ann Surg Oncol. 2014 Jan; 21(1):37-41. PMID: 23982256.
      View in: PubMed
    105. Esserman L, Thompson IM, Reid B. Overdiagnosis and overtreatment in cancer: an opportunity for improvement. JAMA. 2013 Aug 28; 310(8):797-8. PMID: 23896967.
      View in: PubMed
    106. Elson SL, Hiatt RA, Anton-Culver H, Howell LP, Naeim A, Parker BA, Van't Veer LJ, Hogarth M, Pierce JP, Duwors RJ, Hajopoulos K, Esserman L. The Athena Breast Health Network: developing a rapid learning system in breast cancer prevention, screening, treatment, and care. Breast Cancer Res Treat. 2013 Jul; 140(2):417-25. PMID: 23887672.
      View in: PubMed
    107. Alvarado MD, Mohan AJ, Esserman L, Park CC, Harrison BL, Howe RJ, Thorsen C, Ozanne EM. Cost-effectiveness analysis of intraoperative radiation therapy for early-stage breast cancer. Ann Surg Oncol. 2013 Sep; 20(9):2873-80. PMID: 23812769.
      View in: PubMed
    108. Vaughn CJ, Peled AW, Esserman L, Foster RD. Feasibility of Performing Total Skin-Sparing Mastectomy in Patients With Prior Circumareolar Mastopexy or Reduction Mammoplasty Incisions. Ann Plast Surg. 2013 Jun 19. PMID: 23788153.
      View in: PubMed
    109. Mukhtar RA, Yau C, Rosen M, Tandon VJ. Clinically meaningful tumor reduction rates vary by prechemotherapy MRI phenotype and tumor subtype in the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657). Ann Surg Oncol. 2013 Nov; 20(12):3823-30. PMID: 23780381; PMCID: PMC3824937.
    110. Flowers CI, O'Donoghue C, Moore D, Goss A, Kim D, Kim JH, Elias SG, Fridland J, Esserman L. Reducing false-positive biopsies: a pilot study to reduce benign biopsy rates for BI-RADS 4A/B assessments through testing risk stratification and new thresholds for intervention. Breast Cancer Res Treat. 2013 Jun; 139(3):769-77. PMID: 23764994; PMCID: PMC3695318.
    111. Piper M, Peled AW, Foster RD, Moore DH, Esserman L. Total skin-sparing mastectomy: a systematic review of oncologic outcomes and postoperative complications. Ann Plast Surg. 2013 Apr; 70(4):435-7. PMID: 23486127.
      View in: PubMed
    112. DeMichele A, Berry DA, Zujewski J, Hunsberger S, Rubinstein L, Tomaszewski JE, Kelloff G, Perlmutter J, Buxton M, Lyandres J, Albain KS, Benz C, Chien AJ, Haluska P, Leyland-Jones B, Liu MC, Munster P, Olopade O, Park JW, Parker BA, Pusztai L, Tripathy D, Rugo H, Yee D, Esserman L. Developing safety criteria for introducing new agents into neoadjuvant trials. Clin Cancer Res. 2013 Jun 01; 19(11):2817-23. PMID: 23470967; PMCID: PMC4096560.
    113. Peled AW, Esserman L. Reply: The effects of acellular dermal matrix in expander-implant breast reconstruction after total skin-sparing mastectomy. Plast Reconstr Surg. 2013 Feb; 131(2):279e. PMID: 23358028.
      View in: PubMed
    114. Yau C, Sninsky J, Kwok S, Wang A, Degnim A, Ingle JN, Gillett C, Tutt A, Waldman F, Moore D, Esserman L, Benz CC. An optimized five-gene multi-platform predictor of hormone receptor negative and triple negative breast cancer metastatic risk. Breast Cancer Res. 2013; 15(5):R103. PMID: 24172169; PMCID: PMC3978448.
    115. Esserman L, Ozanne E, van't Veer L. Will early detection for breast cancer ever work? Clin Chem. 2013 Jan; 59(1):190-3. PMID: 23193061.
      View in: PubMed
    116. Yee D, Haddad T, Albain K, Barker A, Benz C, Boughey J, Buxton M, Chien AJ, DeMichele A, Dilts D, Elias A, Haluska P, Hogarth M, Hu A, Hytlon N, Kaplan HG, Kelloff GG, Khan Q, Lang J, Leyland-Jones B, Liu M, Nanda R, Northfelt D, Olopade OI, Park J, Parker B, Parkinson D, Pearson-White S, Perlmutter J, Pusztai L, Symmans F, Rugo H, Tripathy D, Wallace A, Wholley D, Van't Veer L, Berry DA, Esserman L. Adaptive trials in the neoadjuvant setting: a model to safely tailor care while accelerating drug development. J Clin Oncol. 2012 Dec 20; 30(36):4584-6; author reply 4588-9. PMID: 23169510.
      View in: PubMed
    117. Khatcheressian JL, Hurley P, Bantug E, Esserman L, Grunfeld E, Halberg F, Hantel A, Henry NL, Muss HB, Smith TJ, Vogel VG, Wolff AC, Somerfield MR, Davidson NE. Breast cancer follow-up and management after primary treatment: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol. 2013 Mar 01; 31(7):961-5. PMID: 23129741.
      View in: PubMed
    118. Wulfkuhle JD, Berg D, Wolff C, Langer R, Tran K, Illi J, Espina V, Pierobon M, Deng J, DeMichele A, Walch A, Bronger H, Becker I, Waldhör C, Höfler H, Esserman L. Molecular analysis of HER2 signaling in human breast cancer by functional protein pathway activation mapping. Clin Cancer Res. 2012 Dec 01; 18(23):6426-35. PMID: 23045247.
      View in: PubMed
    119. Lips EH, Mukhtar RA, Yau C, de Ronde JJ, Livasy C, Carey LA, Loo CE, Vrancken-Peeters MJ, Sonke GS, Berry DA, Van't Veer LJ, Esserman L, Wesseling J, Rodenhuis S, Shelley Hwang E. Lobular histology and response to neoadjuvant chemotherapy in invasive breast cancer. Breast Cancer Res Treat. 2012 Nov; 136(1):35-43. PMID: 22961065.
      View in: PubMed
    120. Petrillo LA, Wolf DM, Kapoun AM, Wang NJ, Barczak A, Xiao Y, Korkaya H, Baehner F, Lewicki J, Wicha M, Park JW, Spellman PT, Gray JW, Van't Veer L, Esserman L. Xenografts faithfully recapitulate breast cancer-specific gene expression patterns of parent primary breast tumors. Breast Cancer Res Treat. 2012 Oct; 135(3):913-22. PMID: 22941572; PMCID: PMC3873871.
    121. Peled AW, Foster RD, Esserman L, Park CC, Hwang ES, Fowble B. Increasing the time to expander-implant exchange after postmastectomy radiation therapy reduces expander-implant failure. Plast Reconstr Surg. 2012 Sep; 130(3):503-9. PMID: 22929235.
      View in: PubMed
    122. Autier P, Esserman L, Flowers CI, Houssami N. Breast cancer screening: the questions answered. Nat Rev Clin Oncol. 2012 10; 9(10):599-605. PMID: 22889976.
      View in: PubMed
    123. Bock M, Moore D, Hwang J, Shumay D, Lawson L, Hamolsky D, Esserman L, Rugo H, Chien AJ, Park J, Munster P, Melisko M. The impact of an electronic health questionnaire on symptom management and behavior reporting for breast cancer survivors. Breast Cancer Res Treat. 2012 Aug; 134(3):1327-35. PMID: 22798157.
      View in: PubMed
    124. Cohen E, Belkora J, Tyler J, Schreiner J, Deering MJ, Grama L, Duggan B, Illi J, Pederson J, Anand A, Teng A, McCreary E, Moore D, Tripathy D, Hogarth M, Lieberman M, Park J, Esserman L. Adoption, acceptability, and accuracy of an online clinical trial matching website for breast cancer. J Med Internet Res. 2012 Jul 11; 14(4):e97. PMID: 22784878; PMCID: PMC3409596.
    125. Ellis MJ, Ding L, Shen D, Luo J, Suman VJ, Wallis JW, Van Tine BA, Hoog J, Goiffon RJ, Goldstein TC, Ng S, Lin L, Crowder R, Snider J, Ballman K, Weber J, Chen K, Koboldt DC, Kandoth C, Schierding WS, McMichael JF, Miller CA, Lu C, Harris CC, McLellan MD, Wendl MC, DeSchryver K, Allred DC, Esserman L, Unzeitig G, Margenthaler J, Babiera GV, Marcom PK, Guenther JM, Leitch M, Hunt K, Olson J, Tao Y, Maher CA, Fulton LL, Fulton RS, Harrison M, Oberkfell B, Du F, Demeter R, Vickery TL, Elhammali A, Piwnica-Worms H, McDonald S, Watson M, Dooling DJ, Ota D, Chang LW, Bose R, Ley TJ, Piwnica-Worms D, Stuart JM, Wilson RK, Mardis ER. Whole-genome analysis informs breast cancer response to aromatase inhibition. Nature. 2012 Jun 10; 486(7403):353-60. PMID: 22722193; PMCID: PMC3383766.
    126. Peled AW, Foster RD, Garwood ER, Moore DH, Ewing CA, Alvarado M, Hwang ES, Esserman L. The effects of acellular dermal matrix in expander-implant breast reconstruction after total skin-sparing mastectomy: results of a prospective practice improvement study. Plast Reconstr Surg. 2012 Jun; 129(6):901e-908e. PMID: 22634688.
      View in: PubMed
    127. Hylton NM, Blume JD, Bernreuter WK, Pisano ED, Rosen MA, Morris EA, Weatherall PT, Lehman CD, Newstead GM, Polin S, Marques HS, Esserman L, Schnall MD. Locally advanced breast cancer: MR imaging for prediction of response to neoadjuvant chemotherapy--results from ACRIN 6657/I-SPY TRIAL. Radiology. 2012 Jun; 263(3):663-72. PMID: 22623692; PMCID: PMC3359517.
    128. Fumagalli D, Bedard PL, Nahleh Z, Michiels S, Sotiriou C, Loi S, Sparano JA, Ellis M, Hylton N, Zujewski JA, Hudis C, Esserman L, Piccart M. A common language in neoadjuvant breast cancer clinical trials: proposals for standard definitions and endpoints. Lancet Oncol. 2012 Jun; 13(6):e240-8. PMID: 22652232.
      View in: PubMed
    129. Chang EI, Peled AW, Foster RD, Lin C, Zeidler KR, Ewing CA, Alvarado M, Hwang ES, Esserman L. Evaluating the feasibility of extended partial mastectomy and immediate reduction mammoplasty reconstruction as an alternative to mastectomy. Ann Surg. 2012 Jun; 255(6):1151-7. PMID: 22470069.
      View in: PubMed
    130. Esserman L, Berry DA, DeMichele A, Carey L, Davis SE, Buxton M, Hudis C, Gray JW, Perou C, Yau C, Livasy C, Krontiras H, Montgomery L, Tripathy D, Lehman C, Liu MC, Olopade OI, Rugo HS, Carpenter JT, Dressler L, Chhieng D, Singh B, Mies C, Rabban J, Chen YY, Giri D, van 't Veer L, Hylton N. Pathologic complete response predicts recurrence-free survival more effectively by cancer subset: results from the I-SPY 1 TRIAL--CALGB 150007/150012, ACRIN 6657. J Clin Oncol. 2012 Sep 10; 30(26):3242-9. PMID: 22649152; PMCID: PMC3434983.
    131. Mukhtar RA, Moore AP, Tandon VJ, Nseyo O, Twomey P, Adisa CA, Eleweke N, Au A, Baehner FL, Moore DH, McGrath MS, Olopade OI, Gray JW, Campbell MJ, Esserman L. Elevated levels of proliferating and recently migrated tumor-associated macrophages confer increased aggressiveness and worse outcomes in breast cancer. Ann Surg Oncol. 2012 Nov; 19(12):3979-86. PMID: 22622474.
      View in: PubMed
    132. Esserman L. Breast cancer recurrence is dictated by high-risk biology, not choice of surgery. Oncology (Williston Park). 2012 May 15; 26(5). PMID: 25192138.
      View in: PubMed
    133. Warren Peled A, Foster RD, Stover AC, Itakura K, Ewing CA, Alvarado M, Hwang ES, Esserman L. Outcomes after total skin-sparing mastectomy and immediate reconstruction in 657 breasts. Ann Surg Oncol. 2012 Oct; 19(11):3402-9. PMID: 22526909.
      View in: PubMed
    134. Horiuchi D, Kusdra L, Huskey NE, Chandriani S, Lenburg ME, Gonzalez-Angulo AM, Creasman KJ, Bazarov AV, Smyth JW, Davis SE, Yaswen P, Mills GB, Esserman L, Goga A. MYC pathway activation in triple-negative breast cancer is synthetic lethal with CDK inhibition. J Exp Med. 2012 Apr 09; 209(4):679-96. PMID: 22430491; PMCID: PMC3328367.
    135. Alvarado M, Ozanne E, Esserman L. Overdiagnosis and overtreatment of breast cancer. Am Soc Clin Oncol Educ Book. 2012; e40-5. PMID: 24451829.
      View in: PubMed
    136. Esserman L, Benz C, Demichele A. Targeting Molecular Aberrations in Breast Cancer: Is It about Time? Am Soc Clin Oncol Educ Book. 2012; 186-91. PMID: 24451732.
      View in: PubMed
    137. Esserman L, Berry DA, Cheang MC, Yau C, Perou CM, Carey L, DeMichele A, Gray JW, Conway-Dorsey K, Lenburg ME, Buxton MB, Davis SE, van't Veer LJ, Hudis C, Chin K, Wolf D, Krontiras H, Montgomery L, Tripathy D, Lehman C, Liu MC, Olopade OI, Rugo HS, Carpenter JT, Livasy C, Dressler L, Chhieng D, Singh B, Mies C, Rabban J, Chen YY, Giri D, Au A, Hylton N. Chemotherapy response and recurrence-free survival in neoadjuvant breast cancer depends on biomarker profiles: results from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657). Breast Cancer Res Treat. 2012 Apr; 132(3):1049-62. PMID: 22198468; PMCID: PMC3332388.
    138. Esserman L, Woodcock J. Accelerating identification and regulatory approval of investigational cancer drugs. JAMA. 2011 Dec 21; 306(23):2608-9. PMID: 22187281.
      View in: PubMed
    139. Loi S, Symmans WF, Bartlett JM, Fumagalli D, Van't Veer L, Forbes JF, Bedard P, Denkert C, Zujewski J, Viale G, Pusztai L, Esserman L, Leyland-Jones BR. Proposals for uniform collection of biospecimens from neoadjuvant breast cancer clinical trials: timing and specimen types. Lancet Oncol. 2011 Nov; 12(12):1162-8. PMID: 21684810.
      View in: PubMed
    140. Esserman L, Shieh Y, Rutgers EJ, Knauer M, Retèl VP, Mook S, Glas AM, Moore DH, Linn S, van Leeuwen FE, van 't Veer LJ. Impact of mammographic screening on the detection of good and poor prognosis breast cancers. Breast Cancer Res Treat. 2011 Dec; 130(3):725-34. PMID: 21892702.
      View in: PubMed
    141. Meyerson AF, Lessing JN, Itakura K, Hylton NM, Wolverton DE, Joe BN, Esserman L, Hwang ES. Outcome of long term active surveillance for estrogen receptor-positive ductal carcinoma in situ. Breast. 2011 Dec; 20(6):529-33. PMID: 21843942; PMCID: PMC4087114.
    142. Ruffell B, Au A, Rugo HS, Esserman L, Hwang ES, Coussens LM. Leukocyte composition of human breast cancer. Proc Natl Acad Sci U S A. 2012 Feb 21; 109(8):2796-801. PMID: 21825174; PMCID: PMC3287000.
    143. Lin C, Buxton MB, Moore D, Krontiras H, Carey L, DeMichele A, Montgomery L, Tripathy D, Lehman C, Liu M, Olapade O, Yau C, Berry D, Esserman L. Locally advanced breast cancers are more likely to present as Interval Cancers: results from the I-SPY 1 TRIAL (CALGB 150007/150012, ACRIN 6657, InterSPORE Trial). Breast Cancer Res Treat. 2012 Apr; 132(3):871-9. PMID: 21796368; PMCID: PMC3975048.
    144. Mukhtar RA, Moore AP, Nseyo O, Baehner FL, Au A, Moore DH, Twomey P, Campbell MJ, Esserman L. Elevated PCNA+ tumor-associated macrophages in breast cancer are associated with early recurrence and non-Caucasian ethnicity. Breast Cancer Res Treat. 2011 Nov; 130(2):635-44. PMID: 21717106.
      View in: PubMed
    145. Esserman L, Moore DH, Tsing PJ, Chu PW, Yau C, Ozanne E, Chung RE, Tandon VJ, Park JW, Baehner FL, Kreps S, Tutt AN, Gillett CE, Benz CC. Biologic markers determine both the risk and the timing of recurrence in breast cancer. Breast Cancer Res Treat. 2011 Sep; 129(2):607-16. PMID: 21597921; PMCID: PMC4324750.
    146. Hatzis C, Pusztai L, Valero V, Booser DJ, Esserman L, Lluch A, Vidaurre T, Holmes F, Souchon E, Wang H, Martin M, Cotrina J, Gomez H, Hubbard R, Chacón JI, Ferrer-Lozano J, Dyer R, Buxton M, Gong Y, Wu Y, Ibrahim N, Andreopoulou E, Ueno NT, Hunt K, Yang W, Nazario A, DeMichele A, O'Shaughnessy J, Hortobagyi GN, Symmans WF. A genomic predictor of response and survival following taxane-anthracycline chemotherapy for invasive breast cancer. JAMA. 2011 May 11; 305(18):1873-81. PMID: 21558518.
      View in: PubMed
    147. Ellis MJ, Suman VJ, Hoog J, Lin L, Snider J, Prat A, Parker JS, Luo J, DeSchryver K, Allred DC, Esserman L, Unzeitig GW, Margenthaler J, Babiera GV, Marcom PK, Guenther JM, Watson MA, Leitch M, Hunt K, Olson JA. Randomized phase II neoadjuvant comparison between letrozole, anastrozole, and exemestane for postmenopausal women with estrogen receptor-rich stage 2 to 3 breast cancer: clinical and biomarker outcomes and predictive value of the baseline PAM50-based intrinsic subtype--ACOSOG Z1031. J Clin Oncol. 2011 Jun 10; 29(17):2342-9. PMID: 21555689; PMCID: PMC3107749.
    148. Ozanne EM, Shieh Y, Barnes J, Bouzan C, Hwang ES, Esserman L. Characterizing the impact of 25 years of DCIS treatment. Breast Cancer Res Treat. 2011 Aug; 129(1):165-73. PMID: 21390494.
      View in: PubMed
    149. Itakura K, Lessing J, Sakata T, Heinzerling A, Vriens E, Wisner D, Alvarado M, Esserman L, Ewing C, Hylton N, Hwang ES. The impact of preoperative magnetic resonance imaging on surgical treatment and outcomes for ductal carcinoma in situ. Clin Breast Cancer. 2011 Mar; 11(1):33-8. PMID: 21421520; PMCID: PMC4508001.
    150. Mukhtar RA, Nseyo O, Campbell MJ, Esserman L. Tumor-associated macrophages in breast cancer as potential biomarkers for new treatments and diagnostics. Expert Rev Mol Diagn. 2011 Jan; 11(1):91-100. PMID: 21171924.
      View in: PubMed
    151. Yau C, Esserman L, Moore DH, Waldman F, Sninsky J, Benz CC. A multigene predictor of metastatic outcome in early stage hormone receptor-negative and triple-negative breast cancer. Breast Cancer Res. 2010; 12(5):R85. PMID: 20946665.
      View in: PubMed
    152. Hogarth M, Hajopoulos K, Young M, Cowles N, Churin J, Hornthal B, Esserman L. The Communication and Care Plan: a novel approach to patient-centered clinical information systems. J Biomed Inform. 2010 Oct; 43(5 Suppl):S6-8. PMID: 20937486.
      View in: PubMed
    153. Braithwaite D, Satariano WA, Sternfeld B, Hiatt RA, Ganz PA, Kerlikowske K, Moore DH, Slattery ML, Tammemagi M, Castillo A, Melisko M, Esserman L, Weltzien EK, Caan BJ. Long-term prognostic role of functional limitations among women with breast cancer. J Natl Cancer Inst. 2010 Oct 06; 102(19):1468-77. PMID: 20861456; PMCID: PMC2950169.
    154. Campbell MJ, Tonlaar NY, Garwood ER, Huo D, Moore DH, Khramtsov AI, Au A, Baehner F, Chen Y, Malaka DO, Lin A, Adeyanju OO, Li S, Gong C, McGrath M, Olopade OI, Esserman L. Proliferating macrophages associated with high grade, hormone receptor negative breast cancer and poor clinical outcome. Breast Cancer Res Treat. 2011 Aug; 128(3):703-711. PMID: 20842526; PMCID: PMC4657137.
    155. Liu LC, Lang JE, Lu Y, Roe D, Hwang SE, Ewing CA, Esserman L, Morita E, Treseler P, Leong SP. Intraoperative frozen section analysis of sentinel lymph nodes in breast cancer patients: a meta-analysis and single-institution experience. Cancer. 2011 Jan 15; 117(2):250-8. PMID: 20818649.
      View in: PubMed
    156. Warren Peled A, Itakura K, Foster RD, Hamolsky D, Tanaka J, Ewing C, Alvarado M, Esserman L, Hwang ES. Impact of chemotherapy on postoperative complications after mastectomy and immediate breast reconstruction. Arch Surg. 2010 Sep; 145(9):880-5. PMID: 20855759.
      View in: PubMed
    157. Esserman L, Kaklamani V. Lessons learned from genetic testing. JAMA. 2010 Sep 01; 304(9):1011-2. PMID: 20810382.
      View in: PubMed
    158. Belkora JK, Teng A, Volz S, Loth MK, Esserman L. Expanding the reach of decision and communication aids in a breast care center: a quality improvement study. Patient Educ Couns. 2011 May; 83(2):234-9. PMID: 20696543.
      View in: PubMed
    159. Vaidya JS, Joseph DJ, Tobias JS, Bulsara M, Wenz F, Saunders C, Alvarado M, Flyger HL, Massarut S, Eiermann W, Keshtgar M, Dewar J, Kraus-Tiefenbacher U, Sütterlin M, Esserman L, Holtveg HM, Roncadin M, Pigorsch S, Metaxas M, Falzon M, Matthews A, Corica T, Williams NR, Baum M. Targeted intraoperative radiotherapy versus whole breast radiotherapy for breast cancer (TARGIT-A trial): an international, prospective, randomised, non-inferiority phase 3 trial. Lancet. 2010 Jul 10; 376(9735):91-102. PMID: 20570343.
      View in: PubMed
    160. Chan LW, Rabban J, Hwang ES, Bevan A, Alvarado M, Ewing C, Esserman L, Fowble B. Is radiation indicated in patients with ductal carcinoma in situ and close or positive mastectomy margins? Int J Radiat Oncol Biol Phys. 2011 May 01; 80(1):25-30. PMID: 20646871.
      View in: PubMed
    161. Esserman L, Thompson I. Solving the overdiagnosis dilemma. J Natl Cancer Inst. 2010 May 05; 102(9):582-3. PMID: 20413743.
      View in: PubMed
    162. Garwood ER, Kumar AS, Baehner FL, Moore DH, Au A, Hylton N, Flowers CI, Garber J, Lesnikoski BA, Hwang ES, Olopade O, Port ER, Campbell M, Esserman L. Fluvastatin reduces proliferation and increases apoptosis in women with high grade breast cancer. Breast Cancer Res Treat. 2010 Jan; 119(1):137-44. PMID: 19728082; PMCID: PMC4087110.
    163. Zakhireh J, Fowble B, Esserman L. Application of screening principles to the reconstructed breast. J Clin Oncol. 2010 Jan 01; 28(1):173-80. PMID: 19884555.
      View in: PubMed
    164. Esserman L, Shieh Y, Thompson I. Rethinking screening for breast cancer and prostate cancer. JAMA. 2009 Oct 21; 302(15):1685-92. PMID: 19843904.
      View in: PubMed
    165. Mukhtar RA, Throckmorton AD, Alvarado MD, Ewing CA, Esserman L, Chiu C, Hwang ES. Bacteriologic features of surgical site infections following breast surgery. Am J Surg. 2009 Oct; 198(4):529-31. PMID: 19800462.
      View in: PubMed
    166. Chen YY, DeVries S, Anderson J, Lessing J, Swain R, Chin K, Shim V, Esserman L, Waldman FM, Hwang ES. Pathologic and biologic response to preoperative endocrine therapy in patients with ER-positive ductal carcinoma in situ. BMC Cancer. 2009 Aug 18; 9:285. PMID: 19689789; PMCID: PMC2744704.
    167. Lang JE, Magbanua MJ, Scott JH, Makrigiorgos GM, Wang G, Federman S, Esserman L, Park JW, Haqq CM. A comparison of RNA amplification techniques at sub-nanogram input concentration. BMC Genomics. 2009 Jul 20; 10:326. PMID: 19619282; PMCID: PMC2724417.
    168. Barker AD, Sigman CC, Kelloff GJ, Hylton NM, Berry DA, Esserman L. I-SPY 2: an adaptive breast cancer trial design in the setting of neoadjuvant chemotherapy. Clin Pharmacol Ther. 2009 Jul; 86(1):97-100. PMID: 19440188.
      View in: PubMed
    169. Olson JA, Budd GT, Carey LA, Harris LA, Esserman L, Fleming GF, Marcom PK, Leight GS, Giuntoli T, Commean P, Bae K, Luo J, Ellis MJ. Improved surgical outcomes for breast cancer patients receiving neoadjuvant aromatase inhibitor therapy: results from a multicenter phase II trial. J Am Coll Surg. 2009 May; 208(5):906-14; discussion 915-6. PMID: 19476859; PMCID: PMC3683862.
    170. Lang JE, Liu LC, Lu Y, Jenkins T, Hwang SE, Esserman L, Ewing CA, Alvarado M, Morita E, Treseler P, Leong SP. Prognostic implications of positive nonsentinel lymph nodes removed during selective sentinel lymphadenectomy for breast cancer. Breast J. 2009 May-Jun; 15(3):242-6. PMID: 19645778.
      View in: PubMed
    171. Belkora JK, Rugo HS, Moore DH, Hutton DW, Chen DF, Esserman L. Oncologist use of the Adjuvant! model for risk communication: a pilot study examining patient knowledge of 10-year prognosis. BMC Cancer. 2009 Apr 28; 9:127. PMID: 19400938; PMCID: PMC2684746.
    172. Zhu J, Sanborn JZ, Benz S, Szeto C, Hsu F, Kuhn RM, Karolchik D, Archie J, Lenburg ME, Esserman L, Kent WJ, Haussler D, Wang T. The UCSC Cancer Genomics Browser. Nat Methods. 2009 Apr; 6(4):239-40. PMID: 19333237.
      View in: PubMed
    173. Braithwaite D, Tammemagi CM, Moore DH, Ozanne EM, Hiatt RA, Belkora J, West DW, Satariano WA, Liebman M, Esserman L. Hypertension is an independent predictor of survival disparity between African-American and white breast cancer patients. Int J Cancer. 2009 Mar 01; 124(5):1213-9. PMID: 19058216.
      View in: PubMed
    174. Garwood ER, Moore D, Ewing C, Hwang ES, Alvarado M, Foster RD, Esserman L. Total skin-sparing mastectomy: complications and local recurrence rates in 2 cohorts of patients. Ann Surg. 2009 Jan; 249(1):26-32. PMID: 19106672.
      View in: PubMed
    175. Throckmorton AD, Esserman L. When informed, all women do not prefer breast conservation. J Clin Oncol. 2009 Feb 01; 27(4):484-6. PMID: 19114690.
      View in: PubMed
    176. Ozanne EM, Braithwaite D, Sepucha K, Moore D, Esserman L, Belkora J. Sensitivity to input variability of the Adjuvant! Online breast cancer prognostic model. J Clin Oncol. 2009 Jan 10; 27(2):214-9. PMID: 19047286.
      View in: PubMed
    177. Tutt A, Wang A, Rowland C, Gillett C, Lau K, Chew K, Dai H, Kwok S, Ryder K, Shu H, Springall R, Cane P, McCallie B, Kam-Morgan L, Anderson S, Buerger H, Gray J, Bennington J, Esserman L, Hastie T, Broder S, Sninsky J, Brandt B, Waldman F. Risk estimation of distant metastasis in node-negative, estrogen receptor-positive breast cancer patients using an RT-PCR based prognostic expression signature. BMC Cancer. 2008 Nov 21; 8:339. PMID: 19025599; PMCID: PMC2631011.
    178. Zakhireh J, Gomez R, Esserman L. Converting evidence to practice: a guide for the clinical application of MRI for the screening and management of breast cancer. Eur J Cancer. 2008 Dec; 44(18):2742-52. PMID: 18977653.
      View in: PubMed
    179. Liu LC, Lang JE, Jenkins T, Lu Y, Ewing CA, Hwang SE, Sokol S, Alvarado M, Esserman L, Morita E, Treseler P, Leong SP. Is it necessary to harvest additional lymph nodes after resection of the most radioactive sentinel lymph node in breast cancer? J Am Coll Surg. 2008 Dec; 207(6):853-8. PMID: 19183531.
      View in: PubMed
    180. Belkora JK, Loth MK, Chen DF, Chen JY, Volz S, Esserman L. Monitoring the implementation of Consultation Planning, Recording, and Summarizing in a breast care center. Patient Educ Couns. 2008 Dec; 73(3):536-43. PMID: 18755564; PMCID: PMC2622737.
    181. Belkora J, Rugo HS, Moore DH, Hutton D, Esserman L. Risk communication with patients with breast cancer: cautionary notes about printing Adjuvant! estimates. Lancet Oncol. 2008 Jul; 9(7):602-3. PMID: 18598923.
      View in: PubMed
    182. Li KL, Partridge SC, Joe BN, Gibbs JE, Lu Y, Esserman L, Hylton NM. Invasive breast cancer: predicting disease recurrence by using high-spatial-resolution signal enhancement ratio imaging. Radiology. 2008 Jul; 248(1):79-87. PMID: 18566170.
      View in: PubMed
    183. Kumar AS, Benz CC, Shim V, Minami CA, Moore DH, Esserman L. Estrogen receptor-negative breast cancer is less likely to arise among lipophilic statin users. Cancer Epidemiol Biomarkers Prev. 2008 May; 17(5):1028-33. PMID: 18463402.
      View in: PubMed
    184. Buchholz TA, Lehman CD, Harris JR, Pockaj BA, Khouri N, Hylton NF, Miller MJ, Whelan T, Pierce LJ, Esserman L, Newman LA, Smith BL, Bear HD, Mamounas EP. Statement of the science concerning locoregional treatments after preoperative chemotherapy for breast cancer: a National Cancer Institute conference. J Clin Oncol. 2008 Feb 10; 26(5):791-7. PMID: 18258988.
      View in: PubMed
    185. Wulfkuhle JD, Speer R, Pierobon M, Laird J, Espina V, Deng J, Mammano E, Yang SX, Swain SM, Nitti D, Esserman L, Belluco C, Liotta LA, Petricoin EF. Multiplexed cell signaling analysis of human breast cancer applications for personalized therapy. J Proteome Res. 2008 Apr; 7(4):1508-17. PMID: 18257519.
      View in: PubMed
    186. Belkora J, Edlow B, Aviv C, Sepucha K, Esserman L. Training community resource center and clinic personnel to prompt patients in listing questions for doctors: follow-up interviews about barriers and facilitators to the implementation of consultation planning. Implement Sci. 2008 Jan 31; 3:6. PMID: 18237380; PMCID: PMC2270865.
    187. Wijayanayagam A, Kumar AS, Foster RD, Esserman L. Optimizing the total skin-sparing mastectomy. Arch Surg. 2008 Jan; 143(1):38-45; discussion 45. PMID: 18209151.
      View in: PubMed
    188. Esserman L, Shieh Y, Park JW, Ozanne EM. A role for biomarkers in the screening and diagnosis of breast cancer in younger women. Expert Rev Mol Diagn. 2007 Sep; 7(5):533-44. PMID: 17892362.
      View in: PubMed
    189. Park JW, Melisko ME, Esserman L, Jones LA, Wollan JB, Sims R. Treatment with autologous antigen-presenting cells activated with the HER-2 based antigen Lapuleucel-T: results of a phase I study in immunologic and clinical activity in HER-2 overexpressing breast cancer. J Clin Oncol. 2007 Aug 20; 25(24):3680-7. PMID: 17704416.
      View in: PubMed
    190. Adduci KM, Annis CE, DeVries S, Chew KL, Boutin J, Magrane G, Ljung BM, Waldman FM, Esserman L. Fluorescence in situ hybridization of ductal lavage samples identifies malignant phenotypes from cytologically normal cells in women with breast cancer. Cancer. 2007 Jun 25; 111(3):185-91. PMID: 17474121.
      View in: PubMed
    191. Ozanne EM, Annis C, Adduci K, Showstack J, Esserman L. Pilot trial of a computerized decision aid for breast cancer prevention. Breast J. 2007 Mar-Apr; 13(2):147-54. PMID: 17319855.
      View in: PubMed
    192. Hwang ES, McLennan JL, Moore DH, Crawford BB, Esserman L, Ziegler JL. Ductal carcinoma in situ in BRCA mutation carriers. J Clin Oncol. 2007 Feb 20; 25(6):642-7. PMID: 17210933.
      View in: PubMed
    193. Wang Y, Moorhead M, Karlin-Neumann G, Wang NJ, Ireland J, Lin S, Chen C, Heiser LM, Chin K, Esserman L, Gray JW, Spellman PT, Faham M. Analysis of molecular inversion probe performance for allele copy number determination. Genome Biol. 2007; 8(11):R246. PMID: 18028543; PMCID: PMC2258201.
    194. Chin K, DeVries S, Fridlyand J, Spellman PT, Roydasgupta R, Kuo WL, Lapuk A, Neve RM, Qian Z, Ryder T, Chen F, Feiler H, Tokuyasu T, Kingsley C, Dairkee S, Meng Z, Chew K, Pinkel D, Jain A, Ljung BM, Esserman L, Albertson DG, Waldman FM, Gray JW. Genomic and transcriptional aberrations linked to breast cancer pathophysiologies. Cancer Cell. 2006 Dec; 10(6):529-41. PMID: 17157792.
      View in: PubMed
    195. Kumar AS, Cureton E, Shim V, Sakata T, Moore DH, Benz CC, Esserman L, Hwang ES. Type and duration of exogenous hormone use affects breast cancer histology. Ann Surg Oncol. 2007 Feb; 14(2):695-703. PMID: 17103262.
      View in: PubMed
    196. Kumar AS, Chen DF, Au A, Chen YY, Leung J, Garwood ER, Gibbs J, Hylton N, Esserman L. Biologic significance of false-positive magnetic resonance imaging enhancement in the setting of ductal carcinoma in situ. Am J Surg. 2006 Oct; 192(4):520-4. PMID: 16978965; PMCID: PMC4087109.
    197. Esserman L, Kumar AS, Herrera AF, Leung J, Au A, Chen YY, Moore DH, Chen DF, Hellawell J, Wolverton D, Hwang ES, Hylton NM. Magnetic resonance imaging captures the biology of ductal carcinoma in situ. J Clin Oncol. 2006 Oct 01; 24(28):4603-10. PMID: 17008702; PMCID: PMC4087112.
    198. Campbell MJ, Esserman L, Zhou Y, Shoemaker M, Lobo M, Borman E, Baehner F, Kumar AS, Adduci K, Marx C, Petricoin EF, Liotta LA, Winters M, Benz S, Benz CC. Breast cancer growth prevention by statins. Cancer Res. 2006 Sep 01; 66(17):8707-14. PMID: 16951186.
      View in: PubMed
    199. Belkora J, Katapodi M, Moore D, Franklin L, Hopper K, Esserman L. Evaluation of a visit preparation intervention implemented in two rural, underserved counties of Northern California. Patient Educ Couns. 2006 Dec; 64(1-3):350-9. PMID: 16904859.
      View in: PubMed
    200. Kumar AS, Benz CC, Esserman L. Clinical trials are required to prove the chemopreventive worth of statins. Arch Intern Med. 2006 May 22; 166(10):1143; author reply 1144. PMID: 16717179.
      View in: PubMed
    201. Kumar AS, Campbell M, Benz CC, Esserman L. A call for clinical trials: lipophilic statins may prove effective in treatment and prevention of particular breast cancer subtypes. J Clin Oncol. 2006 May 01; 24(13):2127; author reply 2127-8. PMID: 16648516.
      View in: PubMed
    202. Esserman L, Sexton R, Yu QQ, Cabello-Inchausti B. Mammographic, sonographic, and pathologic characteristics of Burkitt's lymphoma in a patient referred for diagnostic mammography. AJR Am J Roentgenol. 2006 Apr; 186(4):1029-32. PMID: 16554574.
      View in: PubMed
    203. Ozanne EM, Klemp JR, Esserman L. Breast cancer risk assessment and prevention: a framework for shared decision-making consultations. Breast J. 2006 Mar-Apr; 12(2):103-13. PMID: 16509834.
      View in: PubMed
    204. Daly MB, Axilbund JE, Bryant E, Buys S, Eng C, Friedman S, Esserman L, Farrell CD, Ford JM, Garber JE, Jeter JM, Kohlmann W, Lynch PM, Marcom PK, Nabell LM, Offit K, Osarogiagbon RU, Pasche B, Reiser G, Sutphen R, Weitzel JN. Genetic/familial high-risk assessment: breast and ovarian. J Natl Compr Canc Netw. 2006 Feb; 4(2):156-76. PMID: 16451772.
      View in: PubMed
    205. Kumar AS, Esserman L. Statins: health-promoting agents show promise for breast cancer prevention. Clin Breast Cancer. 2005 Dec; 6(5):455-9. PMID: 16381630.
      View in: PubMed
    206. Esserman L, Ozanne EM, Dowsett M, Slingerland JM. Tamoxifen may prevent both ER+ and ER- breast cancers and select for ER- carcinogenesis: an alternative hypothesis. Breast Cancer Res. 2005; 7(6):R1153-8. PMID: 16457695; PMCID: PMC1410777.
    207. Nanda R, Schumm LP, Cummings S, Fackenthal JD, Sveen L, Ademuyiwa F, Cobleigh M, Esserman L, Lindor NM, Neuhausen SL, Olopade OI. Genetic testing in an ethnically diverse cohort of high-risk women: a comparative analysis of BRCA1 and BRCA2 mutations in American families of European and African ancestry. JAMA. 2005 Oct 19; 294(15):1925-33. PMID: 16234499.
      View in: PubMed
    208. Tan YY, Wu CT, Fan YG, Hwang S, Ewing C, Lane K, Esserman L, Lu Y, Treseler P, Morita E, Leong SP. Primary tumor characteristics predict sentinel lymph node macrometastasis in breast cancer. Breast J. 2005 Sep-Oct; 11(5):338-43. PMID: 16174155.
      View in: PubMed
    209. Fan YG, Tan YY, Wu CT, Treseler P, Lu Y, Chan CW, Hwang S, Ewing C, Esserman L, Morita E, Leong SP. The effect of sentinel node tumor burden on non-sentinel node status and recurrence rates in breast cancer. Ann Surg Oncol. 2005 Sep; 12(9):705-11. PMID: 16079953.
      View in: PubMed
    210. Tan YY, Fan YG, Lu Y, Hwang S, Ewing C, Esserman L, Morita E, Treseler P, Leong SP. Ratio of positive to total number of sentinel nodes predicts nonsentinel node status in breast cancer patients. Breast J. 2005 Jul-Aug; 11(4):248-53. PMID: 15982390.
      View in: PubMed
    211. Partridge SC, Gibbs JE, Lu Y, Esserman L, Tripathy D, Wolverton DS, Rugo HS, Hwang ES, Ewing CA, Hylton NM. MRI measurements of breast tumor volume predict response to neoadjuvant chemotherapy and recurrence-free survival. AJR Am J Roentgenol. 2005 Jun; 184(6):1774-81. PMID: 15908529.
      View in: PubMed
    212. Petricoin EF, Bichsel VE, Calvert VS, Espina V, Winters M, Young L, Belluco C, Trock BJ, Lippman M, Fishman DA, Sgroi DC, Munson PJ, Esserman L, Liotta LA. Mapping molecular networks using proteomics: a vision for patient-tailored combination therapy. J Clin Oncol. 2005 May 20; 23(15):3614-21. PMID: 15908672.
      View in: PubMed
    213. Campbell MJ, Scott J, Maecker HT, Park JW, Esserman L. Immune dysfunction and micrometastases in women with breast cancer. Breast Cancer Res Treat. 2005 May; 91(2):163-71. PMID: 15868444.
      View in: PubMed
    214. Esserman L. Integration of imaging in the management of breast cancer. J Clin Oncol. 2005 Mar 10; 23(8):1601-2. PMID: 15755961.
      View in: PubMed
    215. Foster RD, Hansen SL, Esserman L, Hwang ES, Ewing C, Lane K, Anthony JP. Safety of immediate transverse rectus abdominis myocutaneous breast reconstruction for patients with locally advanced disease. Arch Surg. 2005 Feb; 140(2):196-8; discussion 199-200. PMID: 15724003.
      View in: PubMed
    216. Misell LM, Hwang ES, Au A, Esserman L, Hellerstein MK. Development of a novel method for measuring in vivo breast epithelial cell proliferation in humans. Breast Cancer Res Treat. 2005 Feb; 89(3):257-64. PMID: 15754124.
      View in: PubMed
    217. Lee R, Beattie M, Crawford B, Mak J, Stewart N, Komaromy M, Esserman L, Shaw L, McLennan J, Strachowski L, Luce J, Ziegler J. Recruitment, genetic counseling, and BRCA testing for underserved women at a public hospital. Genet Test. 2005; 9(4):306-12. PMID: 16379544.
      View in: PubMed
    218. Park C, Seid P, Morita E, Iwanaga K, Weinberg V, Quivey J, Hwang ES, Esserman L, Leong SP. Internal mammary sentinel lymph node mapping for invasive breast cancer: implications for staging and treatment. Breast J. 2005 Jan-Feb; 11(1):29-33. PMID: 15647075.
      View in: PubMed
    219. Lang JE, Esserman L, Ewing CA, Rugo HS, Lane KT, Leong SP, Hwang ES. Accuracy of selective sentinel lymphadenectomy after neoadjuvant chemotherapy: effect of clinical node status at presentation. J Am Coll Surg. 2004 Dec; 199(6):856-62. PMID: 15555967.
      View in: PubMed
    220. Ozanne EM, Esserman L. Evaluation of breast cancer risk assessment techniques: a cost-effectiveness analysis. Cancer Epidemiol Biomarkers Prev. 2004 Dec; 13(12):2043-52. PMID: 15598759.
      View in: PubMed
    221. Hwang ES, Nyante SJ, Yi Chen Y, Moore D, DeVries S, Korkola JE, Esserman L, Waldman FM. Clonality of lobular carcinoma in situ and synchronous invasive lobular carcinoma. Cancer. 2004 Jun 15; 100(12):2562-72. PMID: 15197797.
      View in: PubMed
    222. Esserman L. Neoadjuvant chemotherapy for primary breast cancer: lessons learned and opportunities to optimize therapy. Ann Surg Oncol. 2004 Jan; 11(1 Suppl):3S-8S. PMID: 15015703.
      View in: PubMed
    223. Esserman L, Sepucha K, Ozanne E, Hwang ES. Applying the neoadjuvant paradigm to ductal carcinoma in situ. Ann Surg Oncol. 2004 Jan; 11(1 Suppl):28S-36S. PMID: 15015707.
      View in: PubMed
    224. Hwang ES, Esserman L. Neoadjuvant hormonal therapy for ductal carcinoma in situ: trial design and preliminary results. Ann Surg Oncol. 2004 Jan; 11(1 Suppl):37S-43S. PMID: 15015708.
      View in: PubMed
    225. Tjandra D, Wong S, Shen W, Pulliam B, Yu E, Esserman L. An XML message broker framework for exchange and integration of microarray data. Bioinformatics. 2003 Sep 22; 19(14):1844-5. PMID: 14512357.
      View in: PubMed
    226. del Carmen MG, Hughes KS, Halpern E, Rafferty E, Kopans D, Parisky YR, Sardi A, Esserman L, Rust S, Michaelson J. Racial differences in mammographic breast density. Cancer. 2003 Aug 01; 98(3):590-6. PMID: 12879477.
      View in: PubMed
    227. Shim V, Gauthier ML, Sudilovsky D, Mantei K, Chew KL, Moore DH, Cha I, Tlsty TD, Esserman L. Cyclooxygenase-2 expression is related to nuclear grade in ductal carcinoma in situ and is increased in its normal adjacent epithelium. Cancer Res. 2003 May 15; 63(10):2347-50. PMID: 12750248.
      View in: PubMed
    228. Hwang ES, Kinkel K, Esserman L, Lu Y, Weidner N, Hylton NM. Magnetic resonance imaging in patients diagnosed with ductal carcinoma-in-situ: value in the diagnosis of residual disease, occult invasion, and multicentricity. Ann Surg Oncol. 2003 May; 10(4):381-8. PMID: 12734086.
      View in: PubMed
    229. Jabrane-Ferrat N, Nekrep N, Tosi G, Esserman L, Peterlin BM. MHC class II enhanceosome: how is the class II transactivator recruited to DNA-bound activators? Int Immunol. 2003 Apr; 15(4):467-75. PMID: 12663676.
      View in: PubMed
    230. Wu CT, Morita ET, Treseler PA, Esserman L, Hwang ES, Kuerer HM, Santos CL, Leong SP. Failure to harvest sentinel lymph nodes identified by preoperative lymphoscintigraphy in breast cancer patients. Breast J. 2003 Mar-Apr; 9(2):86-90. PMID: 12603380.
      View in: PubMed
    231. Sepucha KR, Belkora JK, Aviv C, Mutchnik S, Esserman L. Improving the quality of decision making in breast cancer: consultation planning template and consultation recording template. Oncol Nurs Forum. 2003 Jan-Feb; 30(1):99-106. PMID: 12515987.
      View in: PubMed
    232. Partridge SC, Gibbs JE, Lu Y, Esserman L, Sudilovsky D, Hylton NM. Accuracy of MR imaging for revealing residual breast cancer in patients who have undergone neoadjuvant chemotherapy. AJR Am J Roentgenol. 2002 Nov; 179(5):1193-9. PMID: 12388497.
      View in: PubMed
    233. Cura MA, Blanco M, Esserman L. Axillary metastasis from a malignant mullerian mixed tumor. Breast J. 2002 Sep-Oct; 8(5):305-6. PMID: 12199759.
      View in: PubMed
    234. Jabrane-Ferrat N, Nekrep N, Tosi G, Esserman L, Peterlin BM. Major histocompatibility complex class II transcriptional platform: assembly of nuclear factor Y and regulatory factor X (RFX) on DNA requires RFX5 dimers. Mol Cell Biol. 2002 Aug; 22(15):5616-25. PMID: 12101253; PMCID: PMC133954.
    235. Euhus DM, Smith KC, Robinson L, Stucky A, Olopade OI, Cummings S, Garber JE, Chittenden A, Mills GB, Rieger P, Esserman L, Crawford B, Hughes KS, Roche CA, Ganz PA, Seldon J, Fabian CJ, Klemp J, Tomlinson G. Pretest prediction of BRCA1 or BRCA2 mutation by risk counselors and the computer model BRCAPRO. J Natl Cancer Inst. 2002 Jun 05; 94(11):844-51. PMID: 12048272.
      View in: PubMed
    236. Campbell MJ, Wollish WS, Lobo M, Esserman L. Epithelial and fibroblast cell lines derived from a spontaneous mammary carcinoma in a MMTV/neu transgenic mouse. In Vitro Cell Dev Biol Anim. 2002 Jun; 38(6):326-33. PMID: 12513120.
      View in: PubMed
    237. Sepucha KR, Belkora JK, Mutchnick S, Esserman L. Consultation planning to help breast cancer patients prepare for medical consultations: effect on communication and satisfaction for patients and physicians. J Clin Oncol. 2002 Jun 01; 20(11):2695-700. PMID: 12039932.
      View in: PubMed
    238. Foster RD, Esserman L, Anthony JP, Hwang ES, Do H. Skin-sparing mastectomy and immediate breast reconstruction: a prospective cohort study for the treatment of advanced stages of breast carcinoma. Ann Surg Oncol. 2002 Jun; 9(5):462-6. PMID: 12052757.
      View in: PubMed
    239. Esserman L. New approaches to the imaging, diagnosis, and biopsy of breast lesions. Cancer J. 2002 May-Jun; 8 Suppl 1:S1-14. PMID: 12075695.
      View in: PubMed
    240. Esserman L, Cowley H, Eberle C, Kirkpatrick A, Chang S, Berbaum K, Gale A. Improving the accuracy of mammography: volume and outcome relationships. J Natl Cancer Inst. 2002 Mar 06; 94(5):369-75. PMID: 11880475.
      View in: PubMed
    241. Esserman L, Hylton N, George T, Weidner N. Contrast-Enhanced Magnetic Resonance Imaging to Assess Tumor Histopathology and Angiogenesis in Breast Carcinoma. Breast J. 1999 Jan; 5(1):13-21. PMID: 11348250.
      View in: PubMed
    242. Ballagh SA, Stover TL, Maragos TG, Reynolds MD, Wolfley GD, Esserman L, Herbst JR, Kirkegaard LW, Teichman SL. A multicenter randomized trial of DIAC for cyclical mastopathy. Prim Care Update Ob Gyns. 1998 Jul 01; 5(4):211. PMID: 10838398.
      View in: PubMed
    243. Igoe S, Collins C, Hamolsky D, Esserman L. Barriers to care and treatment: the challenge of daily radiation therapy. Cancer Pract. 1996 Mar-Apr; 4(2):65-7. PMID: 8715442.
      View in: PubMed
    244. Ginsburg R, Esserman L, Bristow MR. Myocardial performance and extracellular ionized calcium in a severely failing human heart. Ann Intern Med. 1983 May; 98(5 Pt 1):603-6. PMID: 6133487.
      View in: PubMed
    245. Goldman MP, Esserman L, Bausback KN, Camargo CA, Nagel DA. A novel method for emergency immobilization of the wrist during cross-country skiing. Am J Sports Med. 1980 Jul-Aug; 8(4):285-6. PMID: 7396060.
      View in: PubMed